Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

09/02/2017 ​Hepatitis C Under the Watchful of ALBA Synchrotron 02/02/2017 ​The Barcelona Entrepreneurial Spirit Attracts Important Rounds of Funding 26/01/2017 ​SENER, 50 Years In Space! 19/01/2017 Barcelona Synchrotron Park Even Closer 11/01/2017 ALBA Synchrotron Is Also a Tool for the Environment 05/01/2017 ​Barcelona & Catalonia Startup Hub, the Catalan startups showcase
19 20 21 22 23 24 25 26 27 28 29